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Abstract
Acute graft versus host disease (GVHD) is the most critical complication after allogeneic hematopoietic stem cell
transplantation (allo-HSCT). The understanding of major histocompatibility complex (MHC) and the development of
acute GVHD prophylaxis have contributed to decreasing the incidence of severe acute GVHD. However, these
progresses expand the chance of receiving allo-HSCT from human leukocyte antigen (HLA) mismatched donor. In
addition, the expanding of indication for allo-HSCT to elderly patients or patients with organ dysfunction by the
pervasiveness of reduced-intensity conditioning is associated with increased risk of acute GVHD. Unexpectedly,
severe refractory acute GVHD can occur even in allo-HSCT from HLA matched sibling donor. The first line therapy
for severe acute GVHD is corticosteroid, but the second line therapy has not been established and the prognosis of
steroid-resistant acute GVHD remains poor. Recently, the efficacy of human bone marrow mesenchymal stem cell
(MSC) therapy for steroid-resistant acute GVHD has been consistently reported. MSCs are approved as a cell
therapy drug for steroid-resistant acute GVHD in some countries. We here review the history and the future of MSC
therapy for acute GVHD.
Keywords: Mesenchymal stem cell; Immunomodulation; Graft
versus host disease; Hematopoietic stem cell transplantation
Introduction
Although the development of molecular-targeted therapies has
improved prognosis of hematopoietic malignancies for the last couple
of decades, allogeneic hematopoietic stem cell transplantation (allo-
HSCT) remains the only therapeutic approach to relapsed/refractory
diseases. The development of supportive cares for many complications
like infectious diseases and graft versus host disease (GVHD) has
remarkably improved the outcomes of allo-HSCT [1]. However, severe
acute GVHD that occurres within the first 100 days after allo-HSCT is
one of the most critical problems. The frequency and severity of acute
GVHD differ depending on HSC source, human leukocyte antigen
(HLA) disparity, conditioning regimen, acute GVHD prevention, and
comorbidities [2]. The development of GVHD prophylaxis and
reduced-intensity conditioning expanded the chance of receiving allo-
HSCT, but the frequency of refractory severe acute GVHD definitely
increased. A lot of novel drugs, such as anti-thymocyte
immunoglobulin, mycophenolate mofetil, infliximab, have been used
for steroid-resistant acute GVHD. Response rate of these drugs has
been reported to be about 50% (complete response; about 10-30%) and
median overall survival after treatment less than 1 year [3].
Mesenchymal stem cells (MSCs) were discovered as fibroblastic cells
to differentiate to osteo-progenitor cells by Freidenstein et al. [4].
Pittenger et al. indicated that MSCs existed in human bone marrow
[5]. Definition of human MSC includes adherence to plastic dish,
expression of CD105, CD73 and CD90, lack of expression of CD45,
CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR and
differentiation to osteoblast, adipocyte, and chondroblast in vitro [6].
MSCs are isolated from several tissues including bone marrow, fatty
tissue, and umbilical cord with standard adherent method, and these
cells include a heterogeneous cell population. MSCs have
immunomodulatory potential as well as multi-differentiation potential.
MSCs and their progenies support hematopoiesis as niche components
in bone marrow [7,8]. MSCs are most currently investigated as a cell
therapy source because of their accessibility and multipotency [9].
MSC therapy for steroid-resistant acute GVHD has achieved the most
attractive results. In this review we describe the potential and problems
of MSC therapy.
Immunomodulatory function of MSCs
MSC therapy for acute GVHD exploits the immunomodulatory
properties of MSCs. The immunomodulatory effect of MSCs was first
indicated by long term engraftment in a xenogeneic environment in
2000 [10]. Although its mechanisms have not been fully understood,
previous studies have revealed that MSCs inhibited the function of
immune cells via cell to cell contact dependent mechanism and several
soluble immune modulators [11-14].
MSCs can suppress the proliferation of naïve T cells as well as
activated CD4+ helper T (Th) and CD8+ cytotoxic T cells regardless of
major histocompatibility complex (MHC) restriction [15, 16]. MSCs
decrease interferon (IFN)-γ production from Th1 cells and interleukin
(IL)-4 production from Th2 cells. The immunosuppressive effect is
considered to keep T cells in the G0/G1 cell cycle phase via the
downregulation of cyclin D2 expression [17]. MSCs do not expressed
MHC class II and co-stimulatory molecules such as CD40, CD80, and
CD86 [5, 16], which may relate with T cell anergy. MSCs inhibit Th17
cells proliferation and IL-17 production [18]. MSCs can expand
regulatory T cells, which are thought to inhibit allogeneic lymphocyte
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proliferation [19]. MSCs can also suppress the proliferation and IFN-γ
production of natural killer cells [20]. MSCs have been shown to
inhibit the proliferation, immunoglobulin production and chemokine
secretion of activated B cell proliferation [21]. The differentiation from
monocytes or hematopoietic cells to dendritic cells (DCs) and the
maturation of DCs can be impaired by MSCs [22]. In contrast, MSCs
can promote the differentiation to M2 macrophages which abundantly
produce IL-10 [13]. These modulations of immune cells are associated
with many soluble factors released from MSCs, including transforming
growth factor-β1, hepatocyte growth factor, IL-10, indoleamine 2, 3-
dioxygenase, prostaglandin E2, nitric oxide, matrix metalloproteinases,
HLA-G (Figure 1) [11-14]. The secretion of these factors from MSCs
has been shown to be induced by IFN-γ alone, or in combination with
tumor necrosis factor (TNF)-α, IL-1α, or IL-1β [23]. Toll-like receptors
(TLR) also have been reported to be expressed on MSCs and to trigger
the induction of cytokines and chemokines [24]. Thus, various and
complicated mechanisms are involved with immunomodulatory
properties of MSCs.
Figure 1: Interactions between MSCs and immune cells. MSC
inhibits the proliferation, immune response and cytokine
production of B cell (B), Th1 cell, CD8+ cell (Th1), Th17 cell
(Th17), and NK cell (NK). In contrast, MSC promotes the
production of IL-4 and IL-10 from Th2 cell (Th2), and the
expansion of regulatory T cell (Treg). These responses are induced
via soluble factors inclduing hepatocyte growth factor (HGF),
indoleamine 2, 3-dioxygenase (IDO), IFN-γ, IL-4, IL-10, nitric
oxide (NO), prostaglandin E2 (PGE2) and transforming growth
factor-β1 (TGF-β1). CD8+ cytotoxic T cell; CD8+, M2 macrophage;
M2Mφ, dendritic cell; DC.
In addition, little immunogenicity of low expression level of MHC
class I molecule and absence of class II molecules contributes to be
immunomodulatory phenotype [25]. The characteristics allow MSC
therapy from third party donors for acute GVHD. However, the
production of allo-reactive antibodies to MSCs and the rejection of
transplanted MSCs have described [26]. Long term persistence of
MSCs was not observed after HSCT and high-dose MSCs
transplantation for children with severe osteogenesis imperfecta [27].
Thus, whether MSCs derived from third party donor is appropriate
remains controversial.
Clinical studies of MSC therapy for refractory acute GVHD
using individual donors
The first success of MSC therapy for acute GVHD was reported by
Le Blanc et al. in 2004 [28]. A 9-year-old boy with acute lymphoblastic
leukemia who received allo-HSCT from an unrelated donor suffered
from grade IV acute GVHD, though he was treated with steroid pulse
therapy, extracorporeal PUVA, infliximab, decritumab, mycophenolate
mofetil, and methotrexate. MSCs at a dose of 2 × 106 cells/kg isolated
from bone marrow of a haploidentical donor, his mother, were
administered to him. His acute GVHD was rapidly improved within a
week after MSC therapy. Following the amazing result, Le Blanc et al.
conducted a multi-institutional joint phase II experimental study of
MSC therapy for steroid-resistant severe acute GVHD [29]. Thirty of
55 patients with steroid-resistant acute GVHD (grade II, n = 5; grade
III, n = 25; grade IV, n = 25) achieved CR complete response (CR) just
3-63 days (median, 18 days) after MSC therapy. Surprisingly, 90% of
them achieved CR with only a single MSC administration. Both donor
type and cell dose were not associated with overall response. Severity
of acute GVHD also had no significant effect on response. Two-year
overall survival in the patients with CR (52%, 95%CI; 34–70%) was
better than that in the patients with PR or no response (16%, 95%CI;
0–32%, p = 0.018). Subsequently, many studies of MSC therapy for
refractory acute GVHD have been conducted until now (summarized
in Table 1) [29-37]. MSCs were mostly derived from third party donors
in all the studies. Median administered dose of MSCs were 1-2 × 106
cells/kg and median number of doses was 1 to 3. Response was rapidly
observed in responders. CR rate (8-65%) and overall response rate
(16–86%) were varied, which were far superior to conventional salvage
treatment for steroid resistant acute GVHD. Overall survival in the
responders was significantly better compared to non-responders as
reported by Le Blanc. In the three reports containing both pediatric
and adult patients, response in pediatric patients was significantly
superior to that in adult patients [29,35,36]. However, a study
comprising only pediatric patients reported lower complete response
rate (24%) [34]. In that study MSCs were cultured in platelet lysate-
containing medium, which may be associated with the inferior result.
A study for adult patients using MSCs cultured in platelet lysate-
containing medium also showed poor response (CR rate; 8%) [31].
Further studies are needed to clarify the superiority of MSC therapy in
children. Acute toxicity related with MSC infusion was extremely rare
in all the study. In contrast, infectious episodes were reported during
the long term observation. Because the existence of severe acute
GVHD itself contributes to compromised condition, the direct
contribution of MSC therapy to frequency of infectious diseases needs
to be evaluated in the future.
Industrial MSC therapy for acute GVHD
Osiris therapeutics, Inc. developed industrial mesenchymal cells
derived from third-party bone marrow donors, Prochymal, as the
world’s first cell therapy drug. MSCs that are culture-expanded for 5
passages are cryopreserved as product lots. The cells are thawed and
diluted before administration. Kebriaei et al. reported the first
randomized, multicenter phase II trial of Prochymal for acute GVHD
in 2009 [38]. In the study, Prochymal was administered at two different
dose (2 or 8 × 106 cells/kg) with corticosteroid as the first line therapy
to the patients with grade II-IV acute GVHD and the overall response
rate was 93% (CR, 77%; PR, 16%). Subsequently, several studies of
manufactured MSC therapy for steroid-resistant refractory acute
GVHD have been reported (summarized in Table 2) [39-44]. CR and
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overall response rate were 24-58% and 60-93%, which were similar to
the results of MSC therapy from individual donors. However, the
median number doses for a treatment of manufactured MSC therapy
was more than 8, which was so many compared to individual MSC
therapy. In addition, there was no significant difference of CR rate
between Prochymal group and placebo group in a double-blind
placebo-controlled randomized phase III trial (40% and 28%, p = 0.08)
[39]. On the other hand, in a small prospective, open-label,
nonrandomized, multicenter study, CR rate in patients using MSCs in
combination with conventional therapies for refractory acute GVHD
was significantly higher than that in patients treated with only
conventional therapies (61% and 26%, p = 0.02) [43]. Prochymal has
been approved in Canada and New Zealand as a treatment for steroid-
resistant refractory acute GVHD only in children. Another MSC drug,
Temcell HS, which is manufactured according to Prochymal [41,44],
was recently approved for refractory acute GVHD in both adults and
children in Japan. However, further experience is required to make a









infusion (median) CR (%)
CR+PR
(%)
Ringden et al. (30) 8 56 MSD (2), haplo (3), third party (3) 1 1 (1) 63 63
Le Blanc et al. (29) 55 22 MSD (5), haplo (18), third party (69) 1.4 1-5 (2) 55 71
von Bonin et al. (31) 13 58 Third party 0.9 1-5 (2) 8 16
Lucchini et al. (32) 11 10 Third party 1.2 1-5 (NA) 24 73
Herrmann et al. (33) 12 48.5
MSD (1), mismached sibling (1), third
party (10) 1.7-2.3 2-19 (2) 58 33
Resnick et al. (35) 50 19
The same donor as HSC donor (7),
third party (67) 1.1 1-4 (NA) 34 66
Ball et al. (34) 37 7 Haplo (3), third party (34) 2 1-13 (2) 65 86
Introna et al. (36) 31 NA Third party 1.5 2-11 (3) 29 74
Sanchez-Guijo et al.
(37) 25 NA Third party 1.1 2-4 (4) 46 71
Table 1: Summary of MSC therapy for steroid-resistant acute GVHD using individual MSC donors. MSD: HLA-matched sibling donor, haplo:
HLA-haploidentical donor, NA: data not available.







Prasad et al. (40) Phase I/II 12 5 2 or 8 2-21 (8.5) 58 75
Muroi et al. (41) Phase I/II 14 52 2 3-12 (8) 57 93
P. J. Martin et al.
(39) Phase III 163 (Prochymal®) NA 2 8 40 82
81 (placebo) NA 28 73
Kurtzberg et al.
(42) Phase III 75 7.8 2 1-20 (10) NA 61.3
Muroi et al. (44) Phase II/III 25 33 2 4-8 (8) 24 60
Zao et al. (43)
Open-label
non-
randomized 28 (MSC+) 26 1 2-8 (4) 61 75
19 (MSC-) 29 26 42
Table 2: Summary of MSC therapy for steroid-resistant acute GVHD using manufactured MSCs. NA: data not available.
MSC for acute GVHD prophylaxis
Recently, some researchers attempt to utilize MSCs derived from the
same donors as hematopoietic stem cell (HSC) donors for prophylaxis
of acute GVHD. Shinpounova et al. conducted a randomized trial to
examine the efficacy of MSC therapy on acute GVHD prophylaxis [45].
Authors compared 39 patients received MSC therapy for acute GHVD
prophylaxis with 38 patients received standard GVHD prophylaxis. In
the study, MSCs were administered the day when peripheral leukocyte
count reached 109/L at a median dose of 1.2 × 106 cells/kg (range,
0.9-1.65 × 106 cells/kg). The incidence of acute GVHD with grade II-
IV were significantly decreased in the MSC prophylaxis group
compared to the standard prophylaxis group (9.4% versus 29.4%, p =
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0.041). There was no significant difference in donor characteristics and
MSC’s properties between two groups. Gene expression profile analysis
in MSCs suggested that increased gene expression of fibroblast growth
factor receptor 1 (FGFR1) and platelet-derived growth factor receptor
beta (PDGFRB) in MSCs might be related with decrease of the
incidence of acute GVHD. Maziarz et al. conducted phase I dose
escalation study to evaluate the availability and the safety of an
industrial MSC, “allogeneic multipotent adult progenitor cell (MAPC)
(MultiStem®, Athersys, Inc., Cleveland, OH)” for acute GVHD
prophylaxis [46]. Authors compared the efficacy of a single dose
injection of MAPC (1, 5, or 10 × 106 cells/kg, n = 18) with that of once
a week multiple dose injection of MAPC (1 or 5 × 106 cells/kg, n = 18).
No infusion-related toxicities were observed, but 3 patients had a
possible dose-limiting toxicity (DLT) event, within 30 days of MAPC
administration: grade 3 mucositis, grade 3 hypoxic respiratory failure
and grade 3 renal failure, and grade 4 hyperbilirubinemia. Enough
attention to adverse effects should be taken when a high dose of MAPC
administered. There were no differences in GVHD frequency between
the single-dose arm and the multiple-dose arm in this study. The usage
of MSCs for acute GVHD prophylaxis should be carefully considered.
Problems and future directions of MSC therapy for acute
GVHD
There is room for improvement on MSC therapy for refractory acute
GVHD. The quality assurance of MSCs is the most important problem.
As described above, the requirement of repeated administration in
industrial MSC therapy probably could arise from their dysfunction
induced by bulk production. Von Bahr et al. reported that the patients
who received MSCs from passage 1–2 have better survival (75% at 1
year) than those who receive MSCs from passage 3–4 (21%) (p < 0.01)
[47]. In addition, the immune plasticity of MSCs may vary depending
on donors. Many donors are required to secure the quality and
quantity of MSCs. The usage of alternative source, like cord blood (CB)
[48, 49], Wharton’s jelly cells (WJCs) [50], adipose tissue [51], teeth
[52,53], could be one of solutions. Especially, CB and WJCs are
obtainable at delivery without invasive procedure unlike bone marrow
and are/ supposed to be waste materials unless used as a source of
HSCs. In addition, MSCs derived from them have better proliferation
potential than BM-MSCs. These could be strong candidates of
alternative sources of MSCs. There are only a few small pilot studies of
MSC therapy using an alternative source for refractory acute GVHD
[54,55]. In the near future, embryonic stem cells [56] and induced
pluripotent stem cells [57] could be available for MSC source. The
usage of alternative sources is experimental and further studies are
needed for practical clinical applications. In addition, the superiority of
these third donor MSCs to HLA matched donor in MSC therapy has
yet to be elucidated.
MSC therapy has few acute adverse effects but its
immunosuppressive effect may provoke several problems: disease
relapse and susceptibility to infection. Zhao et al. reported that there is
no significant difference in tumor relapse rate, cytomegalovirus
(CMV) and Epstein-Barr virus (EBV) infections between MSC-treated
group and MSC-untreated group in which enrolled patients were
divided by the voluntary principle [43]. Calkoen et al. reported that
only adenovirus infection (ADV) was associated with poor prognosis
in children treated with MSCs although the incidence of CMV, EBV,
and ADV infection was not significantly increased [58]. The authors
indicated that virus-specific T cell activation and proliferation were
impaired by MSC therapy. We need to devote enough attention to viral
infection.
MSC therapy for refractory acute GVHD has been conducted in
many countries because of its attractive results, but there are many
issues to be investigated: cell dose, cell source, culture condition,
quality, long term effect, and late complications. MSC therapy is still on
the way to be established and should be used appropriately in clinical
setting now. Future progress would contribute to establish MSC
therapy as is the case with HSCT.
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